Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer

Miguel Martin, John Mackey, Charles Vogel

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Several phase III trials have been coincident in showing a benefit with adjuvant taxanes in node-positive breast cancer (BC). These trials provide level I evidence of the efficacy of these drugs. The absolute 5-year DFS gain obtained with the taxane-containing regimens in the positive studies ranged from 4% to 7%. However, the regimens including taxanes are more toxic than the conventional anthracyline-containing combinations. Therefore, the pre-treatment identification of the small proportion of patients who actually benefit from taxanes is of major importance. Several attempts have been made to identify the biological peculiarities of the BC patients who benefit most with taxanes, largely based on retrospective subset analyses. Hormone receptor (HR) status, one of the critical determinants of BC biology, had been suggested to be a factor modulating response to adjuvant chemotherapy in general and taxanes in particular. Unfortunately, none of the first-generation adjuvant taxane trials was designed to address the question of the differential efficacy of taxanes in the specific subgroups of HR positive and HR negative BC patients. Indirect (retrospective, unplanned) analysis suggest that the magnitude of benefit from taxanes is somewhat more in the HR negative subset, but the benefit also exists, and is clinically relevant, in patients with HR positive cancers. Therefore, the predictive value of HR status in the selection of patients for adjuvant taxane therapy is low. The predictive value of HER2 status in addition to HR status to select patients for the same purpose remains controversial.

Original languageEnglish
Pages (from-to)127-131
Number of pages5
JournalBreast
Volume16
Issue number2 SUPPL.
DOIs
StatePublished - Nov 6 2007
Externally publishedYes

Fingerprint

Taxoids
Hormones
Breast Neoplasms
Poisons
Adjuvant Chemotherapy
Patient Selection
Therapeutics
Pharmaceutical Preparations

Keywords

  • Adjuvant taxanes
  • Breast cancer
  • Endocrine responsiveness

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. / Martin, Miguel; Mackey, John; Vogel, Charles.

In: Breast, Vol. 16, No. 2 SUPPL., 06.11.2007, p. 127-131.

Research output: Contribution to journalArticle

Martin, Miguel ; Mackey, John ; Vogel, Charles. / Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. In: Breast. 2007 ; Vol. 16, No. 2 SUPPL. pp. 127-131.
@article{e1f374c8dd834b1bb990f02371e1a408,
title = "Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer",
abstract = "Several phase III trials have been coincident in showing a benefit with adjuvant taxanes in node-positive breast cancer (BC). These trials provide level I evidence of the efficacy of these drugs. The absolute 5-year DFS gain obtained with the taxane-containing regimens in the positive studies ranged from 4{\%} to 7{\%}. However, the regimens including taxanes are more toxic than the conventional anthracyline-containing combinations. Therefore, the pre-treatment identification of the small proportion of patients who actually benefit from taxanes is of major importance. Several attempts have been made to identify the biological peculiarities of the BC patients who benefit most with taxanes, largely based on retrospective subset analyses. Hormone receptor (HR) status, one of the critical determinants of BC biology, had been suggested to be a factor modulating response to adjuvant chemotherapy in general and taxanes in particular. Unfortunately, none of the first-generation adjuvant taxane trials was designed to address the question of the differential efficacy of taxanes in the specific subgroups of HR positive and HR negative BC patients. Indirect (retrospective, unplanned) analysis suggest that the magnitude of benefit from taxanes is somewhat more in the HR negative subset, but the benefit also exists, and is clinically relevant, in patients with HR positive cancers. Therefore, the predictive value of HR status in the selection of patients for adjuvant taxane therapy is low. The predictive value of HER2 status in addition to HR status to select patients for the same purpose remains controversial.",
keywords = "Adjuvant taxanes, Breast cancer, Endocrine responsiveness",
author = "Miguel Martin and John Mackey and Charles Vogel",
year = "2007",
month = "11",
day = "6",
doi = "10.1016/j.breast.2007.09.001",
language = "English",
volume = "16",
pages = "127--131",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "2 SUPPL.",

}

TY - JOUR

T1 - Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer

AU - Martin, Miguel

AU - Mackey, John

AU - Vogel, Charles

PY - 2007/11/6

Y1 - 2007/11/6

N2 - Several phase III trials have been coincident in showing a benefit with adjuvant taxanes in node-positive breast cancer (BC). These trials provide level I evidence of the efficacy of these drugs. The absolute 5-year DFS gain obtained with the taxane-containing regimens in the positive studies ranged from 4% to 7%. However, the regimens including taxanes are more toxic than the conventional anthracyline-containing combinations. Therefore, the pre-treatment identification of the small proportion of patients who actually benefit from taxanes is of major importance. Several attempts have been made to identify the biological peculiarities of the BC patients who benefit most with taxanes, largely based on retrospective subset analyses. Hormone receptor (HR) status, one of the critical determinants of BC biology, had been suggested to be a factor modulating response to adjuvant chemotherapy in general and taxanes in particular. Unfortunately, none of the first-generation adjuvant taxane trials was designed to address the question of the differential efficacy of taxanes in the specific subgroups of HR positive and HR negative BC patients. Indirect (retrospective, unplanned) analysis suggest that the magnitude of benefit from taxanes is somewhat more in the HR negative subset, but the benefit also exists, and is clinically relevant, in patients with HR positive cancers. Therefore, the predictive value of HR status in the selection of patients for adjuvant taxane therapy is low. The predictive value of HER2 status in addition to HR status to select patients for the same purpose remains controversial.

AB - Several phase III trials have been coincident in showing a benefit with adjuvant taxanes in node-positive breast cancer (BC). These trials provide level I evidence of the efficacy of these drugs. The absolute 5-year DFS gain obtained with the taxane-containing regimens in the positive studies ranged from 4% to 7%. However, the regimens including taxanes are more toxic than the conventional anthracyline-containing combinations. Therefore, the pre-treatment identification of the small proportion of patients who actually benefit from taxanes is of major importance. Several attempts have been made to identify the biological peculiarities of the BC patients who benefit most with taxanes, largely based on retrospective subset analyses. Hormone receptor (HR) status, one of the critical determinants of BC biology, had been suggested to be a factor modulating response to adjuvant chemotherapy in general and taxanes in particular. Unfortunately, none of the first-generation adjuvant taxane trials was designed to address the question of the differential efficacy of taxanes in the specific subgroups of HR positive and HR negative BC patients. Indirect (retrospective, unplanned) analysis suggest that the magnitude of benefit from taxanes is somewhat more in the HR negative subset, but the benefit also exists, and is clinically relevant, in patients with HR positive cancers. Therefore, the predictive value of HR status in the selection of patients for adjuvant taxane therapy is low. The predictive value of HER2 status in addition to HR status to select patients for the same purpose remains controversial.

KW - Adjuvant taxanes

KW - Breast cancer

KW - Endocrine responsiveness

UR - http://www.scopus.com/inward/record.url?scp=35649011374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35649011374&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2007.09.001

DO - 10.1016/j.breast.2007.09.001

M3 - Article

C2 - 17923408

AN - SCOPUS:35649011374

VL - 16

SP - 127

EP - 131

JO - Breast

JF - Breast

SN - 0960-9776

IS - 2 SUPPL.

ER -